Nitroaspirin

DB12445

small molecule investigational

Deskripsi

Nitroaspirin has been investigated for the treatment of Intermittent Claudication.

Struktur Molekul 2D

Berat 331.28
Wujud -

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1605 Data
Apixaban The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Apixaban.
Dasatinib Dasatinib may increase the anticoagulant activities of Nitroaspirin.
Ursodeoxycholic acid The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Cholic Acid.
Glycocholic acid The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Taurocholic acid.
Obeticholic acid The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Hyodeoxycholic Acid.
Glucosamine Glucosamine may increase the antiplatelet activities of Nitroaspirin.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ibritumomab tiuxetan.
Ibrutinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Nitroaspirin.
Obinutuzumab The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Obinutuzumab.
Pentoxifylline Pentoxifylline may increase the antiplatelet activities of Nitroaspirin.
Rivaroxaban Nitroaspirin may increase the anticoagulant activities of Rivaroxaban.
Tipranavir Tipranavir may increase the antiplatelet activities of Nitroaspirin.
Urokinase Nitroaspirin may increase the anticoagulant activities of Urokinase.
Vitamin E Vitamin E may increase the antiplatelet activities of Nitroaspirin.
Amlodipine Nitroaspirin may decrease the antihypertensive activities of Amlodipine.
Phentermine The risk or severity of hypertension can be increased when Phentermine is combined with Nitroaspirin.
Midodrine The risk or severity of hypertension can be increased when Midodrine is combined with Nitroaspirin.
Eletriptan The risk or severity of hypertension can be increased when Eletriptan is combined with Nitroaspirin.
Isoetharine The risk or severity of hypertension can be increased when Isoetharine is combined with Nitroaspirin.
Ziprasidone The risk or severity of hypertension can be increased when Ziprasidone is combined with Nitroaspirin.
Methysergide The risk or severity of hypertension can be increased when Methysergide is combined with Nitroaspirin.
Cabergoline The risk or severity of hypertension can be increased when Cabergoline is combined with Nitroaspirin.
Zolmitriptan The risk or severity of hypertension can be increased when Zolmitriptan is combined with Nitroaspirin.
Dihydroergotamine The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Nitroaspirin.
Methylergometrine The risk or severity of hypertension can be increased when Methylergometrine is combined with Nitroaspirin.
Norepinephrine The risk or severity of hypertension can be increased when Norepinephrine is combined with Nitroaspirin.
Mirtazapine The risk or severity of hypertension can be increased when Mirtazapine is combined with Nitroaspirin.
Phenylephrine The risk or severity of hypertension can be increased when Phenylephrine is combined with Nitroaspirin.
Phenylpropanolamine The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Nitroaspirin.
Promazine The risk or severity of hypertension can be increased when Promazine is combined with Nitroaspirin.
Droperidol The risk or severity of hypertension can be increased when Droperidol is combined with Nitroaspirin.
Doxapram The risk or severity of hypertension can be increased when Doxapram is combined with Nitroaspirin.
Atropine The risk or severity of hypertension can be increased when Atropine is combined with Nitroaspirin.
Lisuride The risk or severity of hypertension can be increased when Lisuride is combined with Nitroaspirin.
Metaraminol The risk or severity of hypertension can be increased when Metaraminol is combined with Nitroaspirin.
Epinephrine The risk or severity of hypertension can be increased when Epinephrine is combined with Nitroaspirin.
Thioridazine The risk or severity of hypertension can be increased when Thioridazine is combined with Nitroaspirin.
Ergotamine The risk or severity of hypertension can be increased when Ergotamine is combined with Nitroaspirin.
Nicergoline The risk or severity of hypertension can be increased when Nicergoline is combined with Nitroaspirin.
Sufentanil The risk or severity of hypertension can be increased when Sufentanil is combined with Nitroaspirin.
Methoxamine The risk or severity of hypertension can be increased when Methoxamine is combined with Nitroaspirin.
Risperidone The risk or severity of hypertension can be increased when Risperidone is combined with Nitroaspirin.
Isoflurane The risk or severity of hypertension can be increased when Isoflurane is combined with Nitroaspirin.
Propiomazine The risk or severity of hypertension can be increased when Propiomazine is combined with Nitroaspirin.
Alfentanil The risk or severity of hypertension can be increased when Alfentanil is combined with Nitroaspirin.
Orciprenaline The risk or severity of hypertension can be increased when Orciprenaline is combined with Nitroaspirin.
Propofol The risk or severity of hypertension can be increased when Propofol is combined with Nitroaspirin.
Phenmetrazine The risk or severity of hypertension can be increased when Phenmetrazine is combined with Nitroaspirin.
Trifluoperazine The risk or severity of hypertension can be increased when Trifluoperazine is combined with Nitroaspirin.
Pseudoephedrine The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Nitroaspirin.
Benzphetamine The risk or severity of hypertension can be increased when Benzphetamine is combined with Nitroaspirin.
Ritodrine The risk or severity of hypertension can be increased when Ritodrine is combined with Nitroaspirin.
Flupentixol The risk or severity of hypertension can be increased when Flupentixol is combined with Nitroaspirin.
Remifentanil The risk or severity of hypertension can be increased when Remifentanil is combined with Nitroaspirin.
Bitolterol The risk or severity of hypertension can be increased when Bitolterol is combined with Nitroaspirin.
Oxymetazoline The risk or severity of hypertension can be increased when Oxymetazoline is combined with Nitroaspirin.
Diethylpropion The risk or severity of hypertension can be increased when Diethylpropion is combined with Nitroaspirin.
Salmeterol The risk or severity of hypertension can be increased when Salmeterol is combined with Nitroaspirin.
Naratriptan The risk or severity of hypertension can be increased when Naratriptan is combined with Nitroaspirin.
Formoterol The risk or severity of hypertension can be increased when Formoterol is combined with Nitroaspirin.
Frovatriptan The risk or severity of hypertension can be increased when Frovatriptan is combined with Nitroaspirin.
Methoxyflurane The risk or severity of hypertension can be increased when Methoxyflurane is combined with Nitroaspirin.
Ergoloid mesylate The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Nitroaspirin.
Isoprenaline The risk or severity of hypertension can be increased when Isoprenaline is combined with Nitroaspirin.
Arbutamine The risk or severity of hypertension can be increased when Arbutamine is combined with Nitroaspirin.
Dutasteride The risk or severity of hypertension can be increased when Dutasteride is combined with Nitroaspirin.
Halothane The risk or severity of hypertension can be increased when Halothane is combined with Nitroaspirin.
Pergolide The risk or severity of hypertension can be increased when Pergolide is combined with Nitroaspirin.
Desflurane The risk or severity of hypertension can be increased when Desflurane is combined with Nitroaspirin.
Finasteride The risk or severity of hypertension can be increased when Finasteride is combined with Nitroaspirin.
Aripiprazole The risk or severity of hypertension can be increased when Aripiprazole is combined with Nitroaspirin.
Ergometrine The risk or severity of hypertension can be increased when Ergometrine is combined with Nitroaspirin.
Lisdexamfetamine The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Nitroaspirin.
Fenoterol The risk or severity of hypertension can be increased when Fenoterol is combined with Nitroaspirin.
Pirbuterol The risk or severity of hypertension can be increased when Pirbuterol is combined with Nitroaspirin.
Ephedra sinica root The risk or severity of hypertension can be increased when Ephedra sinica root is combined with Nitroaspirin.
Ephedrine The risk or severity of hypertension can be increased when Ephedrine is combined with Nitroaspirin.
Mephentermine The risk or severity of hypertension can be increased when Mephentermine is combined with Nitroaspirin.
Procaterol The risk or severity of hypertension can be increased when Procaterol is combined with Nitroaspirin.
Yohimbine The risk or severity of hypertension can be increased when Yohimbine is combined with Nitroaspirin.
Methotrimeprazine The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Nitroaspirin.
Clenbuterol The risk or severity of hypertension can be increased when Clenbuterol is combined with Nitroaspirin.
Bambuterol The risk or severity of hypertension can be increased when Bambuterol is combined with Nitroaspirin.
MMDA The risk or severity of hypertension can be increased when MMDA is combined with Nitroaspirin.
Midomafetamine The risk or severity of hypertension can be increased when Midomafetamine is combined with Nitroaspirin.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Nitroaspirin.
4-Methoxyamphetamine The risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with Nitroaspirin.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Nitroaspirin.
Tenamfetamine The risk or severity of hypertension can be increased when Tenamfetamine is combined with Nitroaspirin.
Chlorphentermine The risk or severity of hypertension can be increased when Chlorphentermine is combined with Nitroaspirin.

Target Protein

Prostaglandin G/H synthase 2 PTGS2
Prostaglandin G/H synthase 1 PTGS1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 12738997
    Tesei A, Ricotti L, Ulivi P, Medri L, Amadori D, Zoli W: NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. Int J Oncol. 2003 Jun;22(6):1297-302.
  • PMID: 12846439
    Fiorucci S, Del Soldato P: NO-aspirin: mechanism of action and gastrointestinal safety. Dig Liver Dis. 2003 May;35 Suppl 2:S9-19.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul